<DOC>
	<DOCNO>NCT01791881</DOCNO>
	<brief_summary>To compare efficacy safety Hugel-Tox ( Botulinum toxin A , Hugel , Korea ) Botox treatment Essential Blepharospasm get regulatory approval KFDA</brief_summary>
	<brief_title>Therapeutic Confirmatory Clinical Trial Evaluate Safety Efficacy `` Hugeltox Inj . '' Essential Blepharospasm</brief_title>
	<detailed_description />
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Adult age 18 75 year All patient , diagnose essential blepharospasm , Grade 2~4 Severity Spmasm ( Scott 's Method ) Patients undergone surgical surgery treat blepharospmasm like myectomy neurectomy Patients hypersensitivity history botulinum toxin product previously Patients secondary blepharomspasm Patients hemifacialspasm Patients treatment follow drug ; Anticonvulsants , tranquilizer , narcotic , aminoglycoside antibiotic , muscle relaxtants like baclofen etc. , blocker parasympathetic nervous system , levodopa Patients previous injection botulinum toxin product 3 month Patients significant neuromuscular disease like Myasthenia gravis Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>